000			01643 a2200433 4500
005			20250517132343.0
264		0	_c20170425
008			201704s 0 0 eng d
022			_a1769-6658
024	7		_a10.1016/j.canrad.2016.07.101 _2doi
040			_aNLM _beng _cNLM
100	1		_aBazire, L
245	0	0	_aRisks of second malignancies after breast cancer treatment: Long-term results. _h[electronic resource]
260			_bCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique _cFeb 2017
300			_a10-15 p. _bdigital
500			_aPublication Type: Journal Article
650	0	4	_aAntineoplastic Agents, Hormonal _xadverse effects
650	0	4	_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects
650	0	4	_aBreast Neoplasms _xdrug therapy
650	0	4	_aCombined Modality Therapy
650	0	4	_aFemale
650	0	4	_aFrance _xepidemiology
650	0	4	_aHumans
650	0	4	_aIncidence
650	0	4	_aNeoplasms, Radiation-Induced _xepidemiology
650	0	4	_aNeoplasms, Second Primary _xepidemiology
650	0	4	_aOrgans at Risk
650	0	4	_aRadiotherapy, High-Energy _xadverse effects
650	0	4	_aRetrospective Studies
650	0	4	_aRisk Factors
650	0	4	_aSarcoma _xepidemiology
650	0	4	_aTamoxifen _xadverse effects
700	1		_aDe Rycke, Y
700	1		_aAsselain, B
700	1		_aFourquet, A
700	1		_aKirova, Y M
773	0		_tCancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique _gvol. 21 _gno. 1 _gp. 10-15
856	4	0	_uhttps://doi.org/10.1016/j.canrad.2016.07.101 _zAvailable from publisher's website
999			_c26741091 _d26741091